Samsung Bioepis And Organon Get First High-Concentration Adalimumab Nod In US

Firms Receive First FDA Approval For Higher-Strength 100mg/ml Humira Biosimilar

 
• By David Wallace
  
High low 3D words
Samsung Bioepis and Organon are the first to have both a high- and low-concentration adalimumab biosimilar approved in the US • Source: Shutterstock
Generics Bulletin Podcast

Stay ahead of every shift in generics and biosimilars.

Generics Bulletin brings you the latest updates that matter for the off-patent industry.

SpotifyApple PodcastsWebsite

More from Biosimilars

More from Products